Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.36 |
| ▸ | CD4 | P01730 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | GRB2 | P62993 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23030719 | 1.00 | PRCP (0.37) | PRCPPTPN1CD4MDM2TLR2 | |
| SCHEMBL24817624 | 1.00 | PRCP (0.37) | PRCPPTPN1CD4MDM2TLR2 | |
| SCHEMBL24817625 | 1.00 | PRCP (0.37) | PRCPPTPN1CD4MDM2TLR2 | |
| SCHEMBL28714444 | 0.88 | PTPN1 (0.36) | PRCPPTPN1CD4MDM2TLR2 | |
| SCHEMBL23014548 | 0.88 | PRCP (0.42) | PRCPPTPN1MDM2TLR2ACE | |
| SCHEMBL23014549 | 0.88 | PRCP (0.42) | PRCPPTPN1MDM2TLR2ACE | |
| SCHEMBL23014551 | 0.80 | MDM2 (0.48) | PTPN1MDM2TLR2 | |
| SCHEMBL29757411 | 0.80 | MDM2 (0.48) | PTPN1MDM2TLR2 | |
| SCHEMBL23014552 | 0.80 | MDM2 (0.48) | PTPN1MDM2TLR2 | |
| SCHEMBL30962356 | 0.75 | PRCP (0.46) | PRCPMDM2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| EP-4017866-A1 | METHODS OF MAKING INCRETIN ANALOGS | Eli Lilly and Company (US) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | PRCP 501/4885PTPN1 1527/4885CD4 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.